Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Tolerability and long-term survival of fragile or older patients with diffuse large B cell lymphoma (DLBCL) not otherwise specified by R-CDOP

View Full Paper
Ask AI
Bookmark
Share

Authors

CTChuan TianRGRan Guo

Discussion

Loading...

Member takes

Overview

Retrospective analysis of R-CDOP treatment in older DLBCL patients reveals 50% survival, implying tolerability and durable responses.

Key Points

  • Assess the tolerability and long-term survival of older patients with DLBCL treated with R-CDOP.
  • Retrospective analysis of data from patients with DLBCL NOS treated with frontline R-CDOP.
  • Included Rituximab, Cyclophosphamide, liposomal doxorubicin, and prednisone.
  • Assessment of clinical data included blood counts, chemistry, and imaging.
  • Overall survival and relapse-free survival at 5 years are both 50%.
  • No patient died from treatment complications.
  • Nine patients showed durable complete response, and one showed partial response.

Cite This Study

Tian et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2bbhttps://doi.org/10.1182/blood-2025-7223
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term outcomes, survival predictors and up-front treatment patterns in 568 elderly diffuse large b-cell lymphoma patients from LATAM: Is R-CHOP still the first choice for treating patients older than 60 years?2025
  2. 2Determination of the appropriate chemotherapy for patients aged 80 years or older with diffuse large B cell lymphoma2024
  3. 3Predictors of Survival, Treatment Modalities, and Clinical Outcomes of Diffuse Large B-Cell Lymphoma in Patients Older Than 70 Years Still an Unmet Medical Need in 2024 Based on Real-World Evidence2024 · 11 citations
  4. 4R-mini-CHOP preserves efficacy and limits toxicity for patients ≥ 80 years old with DLBCL2025
  5. 5Retrospective analysis of R-CDOP efficacy and safety in frail patients with DLBCL compared to R-CHOP in fit patients2025